We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to...
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.875 | 49.4350282486 | 1.77 | 3.028 | 1.76 | 192691 | 2.59906828 | CS |
4 | -2.255 | -46.0204081633 | 4.9 | 4.9 | 1.62 | 83647 | 2.98922833 | CS |
12 | -0.905 | -25.4929577465 | 3.55 | 5.29 | 1.62 | 128550 | 3.64328833 | CS |
26 | -0.905 | -25.4929577465 | 3.55 | 5.29 | 1.62 | 128550 | 3.64328833 | CS |
52 | -0.905 | -25.4929577465 | 3.55 | 5.29 | 1.62 | 128550 | 3.64328833 | CS |
156 | -0.905 | -25.4929577465 | 3.55 | 5.29 | 1.62 | 128550 | 3.64328833 | CS |
260 | -0.905 | -25.4929577465 | 3.55 | 5.29 | 1.62 | 128550 | 3.64328833 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions